{"title":"干细胞治疗公司被公共基金拯救","authors":"Marta Paterlini","doi":"10.1038/d43978-023-00183-9","DOIUrl":null,"url":null,"abstract":"A government-sponsored investment fund will acquire Holostem, a biotech that produces the only cure for a rare disease that was on the brink of bankruptcy. A government-sponsored investment fund will acquire Holostem, a biotech that produces the only cure for a rare disease that was on the brink of bankruptcy.","PeriodicalId":498086,"journal":{"name":"Nature Italy","volume":" ","pages":"-"},"PeriodicalIF":0.0000,"publicationDate":"2023-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/d43978-023-00183-9.pdf","citationCount":"0","resultStr":"{\"title\":\"Stem-cell therapy company saved by public funds\",\"authors\":\"Marta Paterlini\",\"doi\":\"10.1038/d43978-023-00183-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A government-sponsored investment fund will acquire Holostem, a biotech that produces the only cure for a rare disease that was on the brink of bankruptcy. A government-sponsored investment fund will acquire Holostem, a biotech that produces the only cure for a rare disease that was on the brink of bankruptcy.\",\"PeriodicalId\":498086,\"journal\":{\"name\":\"Nature Italy\",\"volume\":\" \",\"pages\":\"-\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.nature.com/articles/d43978-023-00183-9.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Italy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.nature.com/articles/d43978-023-00183-9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Italy","FirstCategoryId":"1085","ListUrlMain":"https://www.nature.com/articles/d43978-023-00183-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A government-sponsored investment fund will acquire Holostem, a biotech that produces the only cure for a rare disease that was on the brink of bankruptcy. A government-sponsored investment fund will acquire Holostem, a biotech that produces the only cure for a rare disease that was on the brink of bankruptcy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
